Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Plunkett Research, Ltd.
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Life Technologies Corp Enters Into License and Supply Agreement With Novartis AG For Dynabeads

Wednesday, 31 Jul 2013 08:01am EDT 

Life Technologies Corporation announced that the Company has signed a long-term supply and exclusive licensing agreement with Novartis AG for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Life Technologies will provide the Company's proprietary technology, Dynabeads CD3/CD28 CTS, which possess biological properties suited to production of active, therapeutically relevant immune system cells. The agreement includes rights to use Life Technologies' intellectual property to perform the resulting therapy, and is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer. 

Company Quote

-0.35 -0.43%
11:30am EDT